The U.S. FDA has issued an Emergency Use Authorization to permit the emergency use of Eli Lilly’s Investigational Monoclonal Antibody Therapy Bamlanivimab for the treatment of mild to moderate virus.
The U.S. FDA has issued an Emergency Use Authorization to permit the emergency use of Eli Lilly’s Investigational Monoclonal Antibody Therapy Bamlanivimab for the treatment of mild to moderate virus.
BAMLAN? For some odd reason, this brings to mind the Rambam, but no doubt that is just a coincidence and there are so many of them these days.
“Rabbi Moshe ben Maimon was one of the towering figures in the history of the Jewish people. Of him it was said, “From Moshe (Moses) to Moshe (the son of Maimon) there arose none like Moshe.” Among the Jewish people, he is known as the Rambam, an acronym for Rabbi Moshe ben (son of) Maimon (RaMBaM); while universally – for his fame and influence reached far beyond the confines of his own people – he is called Maimonides, the Greek form of “the son of Maimon. Despite his demanding schedule as a full-time physician, Maimonides wrote prolifically, composing philosophical works, ethical and legal response letters, medical treatises and, in his 20s, a commentary on the entire Mishnah.”
Nivimab?
Novimab Corp. is a Pennsylvania Foreign Business Corporation filed on June 22, 2020. The company’s filing status is listed as Active and its File Number is 7077441. The company’s principal address is 5822 Us Steel Tower, 600 Grant Street, Pittsburgh, PA 15206.
Nivolumab, sold under the brand name Opdivo, is a medication used to treat a number of types of cancer. This includes melanoma, lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, colon cancer, and liver cancer. It is used by slow injection into a vein.
Bamlamnivimab – Rambamnivolumab? No doubt any such link is merely a product of a fevered subconscious. And the coincidences just keep on rolling.
“The U.S. FDA has issued an Emergency Use Authorization to permit the emergency use of Eli Lilly’s Investigational Monoclonal Antibody Therapy Bamlanivimab for the treatment of mild to moderate virus.
“Important Information about bamlanivimab
“Bamlanivimab has not been approved by the FDA for any use. It is not known if bamlanivimab is safe and effective for the treatment of COVID-19.
“Important Safety Information
“There are limited clinical data available for bamlanivimab. Serious and unexpected adverse events may occur that have not been previously reported with bamlanivimab use.
“Hypersensitivity Including Anaphylaxis and Infusion-Related Reactions
“There is a potential for serious hypersensitivity reaction, including anaphylaxis, with administration of bamlanivimab. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medications and/or supportive care.
“Infusion-related reactions have been observed with administration of bamlanivimab. Signs and symptoms of infusion-related reactions may include: fever, chills, nausea, headache, bronchospasm, hypotension, angioedema, throat irritation, rash including urticaria, pruritus, myalgia, dizziness.”
https://www.prnewswire.com/news-releases/lillys-neutralizing-antibody-bamlanivimab-ly-cov555-receives-fda-emergency-use-authorization-for-the-treatment-of-recently-diagnosed-covid-19-301169147.html
And to think they don’t call it a cure.
LikeLiked by 1 person
Thank you, Nancy, for continuing to put your investigative skills/”sleuthing ” work to the benefit of those of us who would otherwise remain “in the dark” – which of course, is where the decades-pushers of this tyranny want us!
LikeLike